Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02793102
Other study ID # 14-HPNCL-11
Secondary ID
Status Withdrawn
Phase N/A
First received June 3, 2016
Last updated June 3, 2016
Start date September 2012
Est. completion date March 2015

Study information

Verified date June 2016
Source Fondation Lenval
Contact n/a
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study type Interventional

Clinical Trial Summary

In the literature the use of olfactory dimension in the treatment of anorexia has not been verified experimentally. The investigator hypothesize that the therapeutic use of a dietary nature olfactory stimuli in anorexia nervosa promotes food recovery. The team propose a prospective study over a period of 12 months in which we use the Body Mass Index (BMI) as the primary endpoint of the state of anorexia nervosa patients.


Description:

As part of the unit that specializes in eating disorders in adolescents, we see patients decreased taste and smell sensory abilities. Since 2006, we have implemented various sensory workshops: olfactory, tactile-kinesthetic and auditory. The establishment of this therapeutic practice that is centered on oral sphere and all respect, it was observed a decrease of 30% of the length of hospitalization. All the data we currently have in the field, suggests a rehabituation food odors and facilitate the recall of memories related to food in anorexic patients. However in the literature the use of olfactory dimension in the treatment of anorexia has not been verified experimentally. The investigator hypothesize that the therapeutic use of a dietary nature olfactory stimuli in anorexia nervosa promotes food recovery. The team propose a prospective study over a period of 12 months in which we use the Body Mass Index (BMI) as the primary endpoint of the state of anorexia nervosa patients.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 2015
Est. primary completion date March 2015
Accepts healthy volunteers No
Gender Both
Age group 11 Years to 18 Years
Eligibility Inclusion Criteria:

- Diagnosis of anorexia nervosa according to DMS IV-TR (Diagnostic and Statistical Manual of Mental Disorders) criteria.

- Follow Outpatient care or hospitalization

- Able to respond to the clinical evaluation questionnaires

- Affiliated to the social security system

- Consentement Informed of the legal representative and the patient

Exclusion Criteria:

- Somatic comorbidity associated diabetes, celiac disease, brain tumor.

- Intolerance Odors, predisposition to develop asthma and / or respiratory allergies.

- Pathologie Chronic of nose and sinus.

- Hyposmic Or anosmic.

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label


Related Conditions & MeSH terms


Intervention

Other:
Olfactory workshop
Twenty odorants are selected: 10 evoke a food (including 5 pleasant and unpleasant 5) and 10 suggest a non-food source
Somesthesia workshop
Kinesthetic time or time for moving the body (30 min), and kinesthetic sensations (duration 10 min), and Talk Time
Auditory workshop
Twenty extracts of music tracks (30 seconds each) are built in the same fashion as those used during the workshops, but are different.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Fondation Lenval

Outcome

Type Measure Description Time frame Safety issue
Primary Assess the impact of sensory workshops on BMI Body Mass Indexat 6 months and 12 months The primary endpoint is the M6 and increase maintenance M12 BMI Body Mass Index to Comparaison to baseline and 6 month after and maintenance at month 12 No
See also
  Status Clinical Trial Phase
Withdrawn NCT01501396 - Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite Phase 2
Active, not recruiting NCT01206335 - Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia Phase 2
Completed NCT02524301 - Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study N/A
Active, not recruiting NCT00488072 - Effects of Mirtazapine on Appetite in Advanced Cancer Patients Phase 2
Withdrawn NCT05039385 - Exercise Program in Patients With Anorexia Nervosa (ESATRAL) N/A
Completed NCT03097874 - Adaptive Treatment for Adolescent Anorexia Nervosa N/A
Completed NCT00031785 - Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer Phase 3
Terminated NCT00558558 - Haelan and Nutrition in Cancer Patients Phase 2
Terminated NCT00535015 - Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer Phase 2
Completed NCT00040885 - Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05) Phase 3
Completed NCT00006799 - Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Phase 3
Active, not recruiting NCT03637816 - Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer Phase 2/Phase 3
Completed NCT04007900 - Positive Affect Treatment (PAT) to Target Reward Mechanisms in Anorexia Nervosa N/A
Completed NCT00735540 - Clinical Diagnosis of Teenagers Admitted to Pediatric Departments N/A
Completed NCT00046904 - Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer Phase 3
Completed NCT04803305 - Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia Phase 1
Completed NCT05708404 - Outpatient Treatment of Severe and Enduring Anorexia Nervosa
Completed NCT03283488 - Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care. Phase 2
Recruiting NCT05503147 - Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients (CanPan) Phase 1
Terminated NCT01200602 - Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy Phase 2